On Nov 07, major Wall Street analysts update their ratings for $McKesson (MCK.US)$, with price targets ranging from $535 to $688.
Morgan Stanley analyst Erin Wright maintains with a buy rating, and maintains the target price at $612.
BofA Securities analyst Allen Lutz maintains with a buy rating, and maintains the target price at $635.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $616 to $668.
Wells Fargo analyst Steve Baxter maintains with a hold rating, and maintains the target price at $535.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and adjusts the target price from $652 to $651.
Furthermore, according to the comprehensive report, the opinions of $McKesson (MCK.US)$'s main analysts recently are as follows:
The stock's recent increase of 5% reflects a strong performance that counters the pessimistic view of long-term target risk.
The firm reported that McKesson's results showed robust performance across all segments, with particularly strong second-quarter performance in US Pharma. The expectation of an acceleration in segment EBIT for FY25, based on the midpoint guidance, is seen as encouraging.
McKesson has addressed several concerns and eliminated a number of significant obstacles. The company, along with its peers, has consistently reported strong updates. Additionally, large-cap healthcare appears to be comparatively under-invested and reasonably valued. There seems to be a solid rationale for the company to revert to its recently higher valuation multiples.
Here are the latest investment ratings and price targets for $McKesson (MCK.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
